PITTSBURGH, PA – Doctors at Allegheny Health Network (AHN), led by neurologist Troy Desai, MD, are exploring the use of a new drug to treat relapsing or primary progressive multiple sclerosis (MS). AHN is one of 276+ worldwide participating in the FENhance study, a Phase III clinical trial to assess the safety and efficacy of the drug Fenebrutinib compared to an approved comparator drug for the condition. MS is a disease that occurs when the body’s immune system malfunctions, attacking the brain, spinal cord and optic nerves of the central nervous system. It is the leading cause of nervous sys…